Literature DB >> 9150168

The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size.

R R Brinkman1, M M Mezei, J Theilmann, E Almqvist, M R Hayden.   

Abstract

Prior studies describing the relationship between CAG size and the age at onset of Huntington disease (HD) have focused on affected persons. To further define the relationship between CAG repeat size and age at onset of HD, we now have analyzed a large cohort of affected and asymptomatic at-risk persons with CAG expansion. This cohort numbered 1,049 persons, including 321 at-risk and 728 affected individuals with a CAG size of 29-121 repeats. Kaplan-Meier analysis has provided curves for determining the likelihood of onset at a given age, for each CAG repeat length in the 39-50 range. The curves were significantly different (P < .0005), with relatively narrow 95% confidence intervals (95% CI) (+/-10%). Penetrance of the mutation for HD also was examined. Although complete penetrance of HD was observed for CAG sizes of > or = 42, only a proportion of those with a CAG repeat length of 36-41 showed signs or symptoms of HD within a normal life span. These data provide information concerning the likelihood of being affected, by a specific age, with a particular CAG size, and they may be useful in predictive-testing programs and for the design of clinical trials for persons at increased risk for HD.

Entities:  

Mesh:

Year:  1997        PMID: 9150168      PMCID: PMC1712445     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  49 in total

1.  Analysis of the huntingtin gene reveals a trinucleotide-length polymorphism in the region of the gene that contains two CCG-rich stretches and a correlation between decreased age of onset of Huntington's disease and CAG repeat number.

Authors:  D C Rubinsztein; D E Barton; B C Davison; M A Ferguson-Smith
Journal:  Hum Mol Genet       Date:  1993-10       Impact factor: 6.150

2.  Mutation size and age at onset in Huntington's disease.

Authors:  D Craufurd; A Dodge
Journal:  J Med Genet       Date:  1993-12       Impact factor: 6.318

3.  Late onset of Huntington's disease.

Authors:  R H Myers; D S Sax; M Schoenfeld; E D Bird; P A Wolf; J P Vonsattel; R F White; J B Martin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-06       Impact factor: 10.154

4.  Correlation between the onset age of Huntington's disease and length of the trinucleotide repeat in IT-15.

Authors:  O C Stine; N Pleasant; M L Franz; M H Abbott; S E Folstein; C A Ross
Journal:  Hum Mol Genet       Date:  1993-10       Impact factor: 6.150

5.  Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA).

Authors:  R Koide; T Ikeuchi; O Onodera; H Tanaka; S Igarashi; K Endo; H Takahashi; R Kondo; A Ishikawa; T Hayashi
Journal:  Nat Genet       Date:  1994-01       Impact factor: 38.330

6.  Dynamic mutation in Dutch Huntington's disease patients: increased paternal repeat instability extending to within the normal size range.

Authors:  K E De Rooij; P A De Koning Gans; M I Skraastad; R D Belfroid; M Vegter-Van Der Vlis; R A Roos; E Bakker; G J Van Ommen; J T Den Dunnen; M Losekoot
Journal:  J Med Genet       Date:  1993-12       Impact factor: 6.318

7.  A study of the Huntington's disease associated trinucleotide repeat in the Scottish population.

Authors:  L H Barron; J P Warner; M Porteous; S Holloway; S Simpson; R Davidson; D J Brock
Journal:  J Med Genet       Date:  1993-12       Impact factor: 6.318

8.  Huntington's disease in Grampian region: correlation of the CAG repeat number and the age of onset of the disease.

Authors:  S A Simpson; M J Davidson; L H Barron
Journal:  J Med Genet       Date:  1993-12       Impact factor: 6.318

9.  Dentatorubral and pallidoluysian atrophy expansion of an unstable CAG trinucleotide on chromosome 12p.

Authors:  S Nagafuchi; H Yanagisawa; K Sato; T Shirayama; E Ohsaki; M Bundo; T Takeda; K Tadokoro; I Kondo; N Murayama
Journal:  Nat Genet       Date:  1994-01       Impact factor: 38.330

10.  Molecular features of the CAG repeats and clinical manifestation of Machado-Joseph disease.

Authors:  H Maruyama; S Nakamura; Z Matsuyama; T Sakai; M Doyu; G Sobue; M Seto; M Tsujihata; T Oh-i; T Nishio
Journal:  Hum Mol Genet       Date:  1995-05       Impact factor: 6.150

View more
  105 in total

1.  Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.

Authors:  P H Reddy; V Charles; M Williams; G Miller; W O Whetsell; D A Tagle
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

2.  Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative.

Authors:  Andrew T N Tebbenkamp; Cameron Green; Guilian Xu; Eileen M Denovan-Wright; Aaron C Rising; Susan E Fromholt; Hilda H Brown; Debbie Swing; Ronald J Mandel; Lino Tessarollo; David R Borchelt
Journal:  Hum Mol Genet       Date:  2011-04-22       Impact factor: 6.150

3.  Genetic background modulates behavioral impairments in R6/2 mice and suggests a role for dominant genetic modifiers in Huntington’s disease pathogenesis.

Authors:  Randi-Michelle Cowin; Nghiem Bui; Deanna Graham; Jennie R Green; Lisa A Yuva-Paylor; Andreas Weiss; Richard Paylor
Journal:  Mamm Genome       Date:  2012-06       Impact factor: 2.957

Review 4.  Role of manganese in neurodegenerative diseases.

Authors:  Aaron B Bowman; Gunnar F Kwakye; Elena Herrero Hernández; Michael Aschner
Journal:  J Trace Elem Med Biol       Date:  2011-10-01       Impact factor: 3.849

Review 5.  Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Authors:  Ina Han; YiMei You; Jeffrey H Kordower; Scott T Brady; Gerardo A Morfini
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

6.  Modeling Huntington's disease in cells, flies, and mice.

Authors:  S Sipione; E Cattaneo
Journal:  Mol Neurobiol       Date:  2001-02       Impact factor: 5.590

7.  Replication of twelve association studies for Huntington's disease residual age of onset in large Venezuelan kindreds.

Authors:  J M Andresen; J Gayán; S S Cherny; D Brocklebank; G Alkorta-Aranburu; E A Addis; L R Cardon; D E Housman; N S Wexler
Journal:  J Med Genet       Date:  2006-10-03       Impact factor: 6.318

Review 8.  Apoptotic cascades as possible targets for inhibiting cell death in Huntington's disease.

Authors:  Lindsay R Pattison; Mark R Kotter; Dean Fraga; Raphael M Bonelli
Journal:  J Neurol       Date:  2006-09-22       Impact factor: 4.849

9.  The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans.

Authors:  James F Morley; Heather R Brignull; Jill J Weyers; Richard I Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-16       Impact factor: 11.205

10.  Progressive synaptic pathology of motor cortical neurons in a BAC transgenic mouse model of Huntington's disease.

Authors:  J Spampanato; X Gu; X W Yang; I Mody
Journal:  Neuroscience       Date:  2008-09-18       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.